Pacira BioSciences, Inc. (PCRX) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended September 30, 2024. Pacira BioSciences, Inc. is a biopharmaceutical company focused on non-opioid pain therapies. Its core commercial products include EXPAREL (long-acting local analgesic), ZILRETTA (extended-release intra-articular injection for osteoarthritis), and iovera (cryoanalgesia device). The company operates as a single reportable segment.
Key Financial Metrics
| Metric | Q3 2024 | Q3 2023 | YTD 9M 2024 | YTD 9M 2023 |
|---|---|---|---|---|
| Total Revenues | $168.6M | $163.9M | $513.7M | $493.7M |
| Net Product Sales | $167.7M | $163.6M | $509.9M | $492.5M |
| Net (Loss) Income | $(143.5M) | $10.9M | $(115.6M) | $17.1M |
| Diluted EPS | $(3.11) | $0.23 | $(2.50) | $0.37 |
| Operating Cash Flow (9M) | $156.3M | $107.1M | - | - |
| Cash & Investments | $453.8M | - | - | - |
| Total Debt (Carrying Value) | $587.4M | - | - | - |
Note: Q3 2024 results include a non-cash goodwill impairment charge of $163.2M.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 3% in Q3 and 4% YTD compared to the prior year. EXPAREL revenue grew 3% (Q3) and 2% (YTD), while iovera revenue grew 8% (Q3) and 20% (YTD). ZILRETTA revenue declined 1% in Q3 but grew 3% YTD.
- Goodwill Impairment: The company recorded a full impairment of its $163.2M goodwill balance in Q3 2024. This was triggered by the FDA approval of a generic competitor to EXPAREL, a court ruling invalidating a key patent, and a decline in stock price.
- Debt Restructuring: In May 2024, the company issued $287.5M of 2029 Convertible Senior Notes. Proceeds were used to repurchase $200M of 2025 Convertible Senior Notes (resulting in a $7.5M gain on extinguishment) and fund a $25M share repurchase.
- Restructuring: The company initiated a restructuring plan in February 2024, incurring $7.7M in charges YTD related to executive team reshaping and resource reallocation.
Outlook, Risks, and Management Commentary
- Reimbursement Milestones: CMS established a permanent J-code for EXPAREL (J0666) effective January 1, 2025. Additionally, EXPAREL and iovera qualify for separate Medicare reimbursement under the NOPAIN Act starting January 2025, expected to increase reimbursement rates in outpatient settings.
- Patent Litigation: A U.S. District Court ruled in August 2024 that the '495 patent protecting EXPAREL was invalid. The company has filed an appeal. A generic version of EXPAREL received FDA approval in July 2024. The company is pursuing four other patent infringement lawsuits against the generic manufacturer.
- Liquidity: As of September 30, 2024, the company held $246M in cash and cash equivalents and $208M in short-term investments. Management believes current resources are sufficient to fund operations for the next 12 months.
- Pipeline: PCRX-201, a gene therapy candidate for osteoarthritis, received RMAT designation from the FDA in February 2024. New 104-week safety and efficacy data is expected to be presented in November 2024.
Investor Verification Checklist
- Patent Appeal Status: Monitor the outcome of the appeal regarding the invalidation of the '495 patent and the status of the four pending patent infringement lawsuits against eVenus.
- Generic Impact: Assess the actual market share erosion of EXPAREL following the July 2024 FDA approval of the generic competitor.
- Reimbursement Implementation: Verify the uptake and billing success of the new EXPAREL J-code and NOPAIN Act reimbursements starting January 2025.
- Debt Covenants: Confirm continued compliance with the Senior Secured Net Leverage Ratio and Fixed Charge Coverage Ratio covenants under the Term Loan A facility.
- PCRX-201 Data: Review the 104-week clinical data presentation at the ACR Convergence meeting in November 2024 for indications of commercial viability.